Glenmark Pharma Reports Q2 FY27 Results with 20% Like-for-Like Revenue Growth
Glenmark Pharmaceuticals Ltd 路 Investor Presentation 路 05 Nov 2026, 10:55 pm
Glenmark Pharma Reports Q2 FY27 Results with 20% Like-for-Like Revenue Growth Glenmark Pharmaceuticals reported Q2 FY27 consolidated revenue of Rs. 42,473 Mn, delivering ~20% like-for-like YoY growth and 5.7% QoQ growth. EBITDA stood at Rs. 8,638 Mn with a 20.3% margin, while adjusted PAT reached Rs. 4,852 Mn with an 11.4% margin. Key regional growth drivers included Emerging Markets (+33.2% YoY), North America core business (~31% YoY), India formulations (~14% YoY like-for-like), and Europe (+6.2% YoY). Consolidated R&D expense totaled Rs. 3,449 Mn as the company advanced its clinical oncology pipeline toward commercialization.
Original exchange filing (PDF)
More announcements from Glenmark Pharmaceuticals Ltd
- Ichnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301 路 18 Nov 2026
- Glenmark Pharmaceuticals Inc., USA Launches Authorised Generic of INLYTA (axitinib) Tablets, 1 mg and 5mg 路 16 Nov 2026
- Schedule of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Initmation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst / Institutional Investor Meetings 路 10 Nov 2026
- Transcript of the Earnings Call 路 09 Nov 2026
- Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 路 06 Nov 2026
